A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...

Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...

India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...

Prostate cancer affects one in five Australian men, making it the most common cancer in the country. Now, researchers at the ...

Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers ...